Orthofix CLO auto-sells 2,775 shares for taxes

Orthofix Medical Inc. chief legal officer Jorge Andres Cedron reported automatic sales of common stock to cover tax withholding on recently settled restricted stock units.

Rhea-AI Filing Summary

Orthofix Medical Inc. chief legal officer Jorge Andres Cedron reported automatic sales of common stock to cover tax withholding on recently settled restricted stock units. A total of 2,775 shares were sold in open‑market transactions on March 4–5 under a pre-existing, committee‑mandated sell-to-cover requirement.

The shares were sold at weighted-average prices of $12.9163 and $12.5508 per share across multiple trades within specified ranges, with no discretion exercised by Cedron. Following these transactions, he beneficially owns 62,749 shares of Orthofix common stock, including 53,902 previously reported restricted stock units.

Insider Trade Summary

Net Seller: 2,775 shares

Net Sell 2 txns

Insider Cedron Jorge Andres

Role CLO

Sold 2,775 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,370	$12.5508	$17K
Sale	Common Stock	1,405	$12.9163	$18K

Holdings After Transaction: Common Stock — 62,749 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
3. F3. Includes 53,902 previously reported restricted stock units.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

FAQ

What insider transaction did Orthofix (OFIX) report for Jorge Andres Cedron?

Orthofix reported that CLO Jorge Andres Cedron sold 2,775 shares of common stock. These were automatic sales to cover tax withholding tied to restricted stock unit settlements under a pre-approved sell-to-cover arrangement, rather than discretionary open-market selling.

How many Orthofix (OFIX) shares did the CLO sell and on which dates?

Cedron’s Form 4 shows sales totaling 2,775 Orthofix common shares. He sold 1,405 shares on March 4, 2026 and 1,370 shares on March 5, 2026, with both transactions designated as open-market sales executed for tax withholding purposes.

At what prices were the Orthofix (OFIX) CLO’s shares sold in the Form 4?

The filing reports weighted-average sale prices of $12.9163 and $12.5508 per Orthofix share. Footnotes explain these represent multiple trades executed within price ranges of $12.80–$13.03 and $12.48–$12.72, respectively, across the two transaction dates.

Why were Orthofix (OFIX) shares sold by CLO Jorge Andres Cedron?

The shares were sold solely to satisfy tax withholding obligations upon settlement of restricted stock units. A pre-existing sell-to-cover requirement, approved by the board’s Compensation and Talent Development Committee, mandated these sales, leaving Cedron with no discretion over whether or when to sell.

How many Orthofix (OFIX) shares does the CLO still own after these sales?

After completing the tax-related sales, Cedron beneficially owns 62,749 Orthofix common shares. This figure includes 53,902 previously reported restricted stock units, meaning most of his reported position remains tied to equity awards that have not yet fully converted into unrestricted shares.

What type of ownership does the Orthofix (OFIX) Form 4 report for these shares?

The transactions are reported as direct ownership of Orthofix common stock by Cedron. The filing classifies both trades as non-derivative, directly held shares with an ownership code of “D,” and does not reference any intermediary entities such as trusts, partnerships, or family investment vehicles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cedron Jorge Andres

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CLO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		1,405	D	$12.9163(2)	64,119(3)	D
Common Stock	03/05/2026		S(1)		1,370	D	$12.5508(4)	62,749(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 53,902 previously reported restricted stock units.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ Jorge Andres Cedron	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.